一种适应小鼠的减毒活流感病毒的开发，该病毒允许对减毒活流感病毒疫苗安全性的增强进行体内分析。
Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.
作者信息
Cox Andrew, Baker Steven F, Nogales Aitor, Martínez-Sobrido Luis, Dewhurst Stephen
机构信息
Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.
Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA
出版信息
J Virol. 2015 Mar;89(6):3421-6. doi: 10.1128/JVI.02636-14. Epub 2014 Dec 31.
Abstract
The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.
摘要
减毒活流感病毒疫苗（LAIV）优先推荐用于2至49岁的人群，但由于安全问题，尚未被批准用于2岁以下儿童或哮喘患者。因此，提高安全性是可取的。在此，我们描述了一种致病性降低的小鼠LAIV，它在高剂量时仍保持致死性，并进一步证明我们可以通过NS1内的突变在体内提高安全性。该模型可能允许对改良的LAIV进行初步安全性分析。
相似文献
1
Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.
J Virol. 2015 Mar;89(6):3421-6. doi: 10.1128/JVI.02636-14. Epub 2014 Dec 31.
2
Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
mBio. 2019 Sep 17;10(5):e02180-19. doi: 10.1128/mBio.02180-19.
3
Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.
Expert Rev Vaccines. 2015;14(10):1313-29. doi: 10.1586/14760584.2015.1075883. Epub 2015 Aug 6.
4
Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.
J Virol. 2014 Jun;88(12):7016-23. doi: 10.1128/JVI.00100-14. Epub 2014 Apr 9.
5
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
Vaccine. 2009 Jun 8;27(28):3744-53. doi: 10.1016/j.vaccine.2009.03.082. Epub 2009 Apr 17.
6
Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine.
Viruses. 2018 Oct 15;10(10):560. doi: 10.3390/v10100560.
7
Live attenuated influenza vaccine in children.
Semin Pediatr Infect Dis. 2006 Oct;17(4):206-12. doi: 10.1053/j.spid.2006.08.007.
8
Development of a dual-protective live attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene.
Arch Virol. 2015 Jul;160(7):1729-40. doi: 10.1007/s00705-015-2442-y. Epub 2015 May 12.
9
Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
Pediatr Infect Dis J. 2001 Dec;20(12):1124-31. doi: 10.1097/00006454-200112000-00006.
10
Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.
Expert Rev Vaccines. 2015 Mar;14(3):395-412. doi: 10.1586/14760584.2015.979159. Epub 2015 Jan 2.
引用本文的文献
1
Abortive Infection of Animal Cells: What Goes Wrong.
Annu Rev Virol. 2024 Sep;11(1):193-213. doi: 10.1146/annurev-virology-100422-023037. Epub 2024 Aug 30.
2
Both Humoral and Cellular Immunity Limit the Ability of Live Attenuated Influenza Vaccines to Promote T Cell Responses.
J Immunol. 2024 Jan 1;212(1):107-116. doi: 10.4049/jimmunol.2300343.
3
Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups.
J Virol. 2022 Oct 26;96(20):e0087122. doi: 10.1128/jvi.00871-22. Epub 2022 Oct 3.
4
Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine.
Microbiol Spectr. 2022 Jun 29;10(3):e0007822. doi: 10.1128/spectrum.00078-22. Epub 2022 May 18.
5
A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines.
Viruses. 2021 Jun 30;13(7):1278. doi: 10.3390/v13071278.
6
Recombinant Live Attenuated Influenza Virus Expressing Conserved G-Protein Domain in a Chimeric Hemagglutinin Molecule Induces G-Specific Antibodies and Confers Protection against Respiratory Syncytial Virus.
Vaccines (Basel). 2020 Dec 1;8(4):716. doi: 10.3390/vaccines8040716.
7
A Mutated PB1 Residue 319 Synergizes with the PB2 N265S Mutation of the Live Attenuated Influenza Vaccine to Convey Temperature Sensitivity.
Viruses. 2020 Oct 31;12(11):1246. doi: 10.3390/v12111246.
8
Impact of Pre-Existing Immunity on Live Attenuated Influenza Vaccine-Induced Cross-Protective Immunity.
Vaccines (Basel). 2020 Aug 20;8(3):459. doi: 10.3390/vaccines8030459.
9
Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins and .
Front Microbiol. 2019 Dec 17;10:2862. doi: 10.3389/fmicb.2019.02862. eCollection 2019.
10
A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.
J Virol. 2020 Jan 31;94(4). doi: 10.1128/JVI.01065-19.
本文引用的文献
1
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season.
MMWR Morb Mortal Wkly Rep. 2014 Aug 15;63(32):691-7.
2
Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development.
J Virol. 2014 Sep;88(18):10525-40. doi: 10.1128/JVI.01565-14. Epub 2014 Jun 25.
3
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.
J Virol. 2014 Mar;88(6):3432-42. doi: 10.1128/JVI.03004-13. Epub 2014 Jan 8.
4
Influenza virus hemagglutinin stalk-based antibodies and vaccines.
Curr Opin Virol. 2013 Oct;3(5):521-30. doi: 10.1016/j.coviro.2013.07.007. Epub 2013 Aug 24.
5
Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.
Sci Transl Med. 2013 Aug 14;5(198):198ra107. doi: 10.1126/scitranslmed.3006637.
6
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
J Virol. 2013 Oct;87(19):10435-46. doi: 10.1128/JVI.01715-13. Epub 2013 Jul 31.
7
Protection against lethal influenza with a viral mimic.
J Virol. 2013 Aug;87(15):8591-605. doi: 10.1128/JVI.01081-13. Epub 2013 May 29.
8
Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice.
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9481-6. doi: 10.1073/pnas.1307473110. Epub 2013 May 20.
9
Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses.
Vaccine. 2012 May 21;30(24):3691-702. doi: 10.1016/j.vaccine.2012.03.025. Epub 2012 Mar 24.
10
The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing.
Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2549-57. doi: 10.1007/s10096-012-1595-9. Epub 2012 Mar 14.
Zotero 插件